Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Auteurs : Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000515